Drug Trial Radar · NCT05595460
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21
Actual
Start
Oct 10, 2022
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- RayzeBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Conditions
- SCLC,Extensive Stage
Interventions
RYZ101 Dose Level 1Drug
Dose Level 1
RYZ101 Dose Level 2Drug
Dose Level 2
RYZ101 Dose Level 3Drug
Dose Level 3
RYZ101 Dose Level -1Drug
Dose Level -1
AtezolizumabDrug
Atezolizumab
CarboplatinDrug
Carboplatin
EtoposideDrug
Etoposide
Primary outcomes
What the sponsor says the trial is designed to measure.
- RP2DTime frame: 42 days of study treatment
- Safety and tolerability of RYZ101 in combination with SoCTime frame: Up to 50 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Research Facility
Los Angeles, California
Research Facility
San Francisco, California
Research Facility
Jacksonville, Florida
Research Facility
Miami, Florida
Research Facility
Orlando, Florida
Research Facility
Iowa City, Iowa
Reserach Facility
Lexington, Kentucky
Research Facility
Grand Rapids, Michigan
Research Facility
Rochester, Minnesota
Research Facility
St Louis, Missouri
Research Facility
Omaha, Nebraska
Research Facility
Salt Lake City, Utah
Research Facility
San Juan, Puerto Rico, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.